ASCT2 promotes GD2+ SCLC cells to take in glutamine to enhance the malignant phenotypes of tumor cells through activation of the mTORC1 signaling axis (Esaki et al., 2018). Here, SLC1A5 is linked to small cell lung carcinoma.